AR104020A1 - Métodos y composiciones para inhibir la interacción de menina con proteínas mill - Google Patents
Métodos y composiciones para inhibir la interacción de menina con proteínas millInfo
- Publication number
- AR104020A1 AR104020A1 ARP160100689A ARP160100689A AR104020A1 AR 104020 A1 AR104020 A1 AR 104020A1 AR P160100689 A ARP160100689 A AR P160100689A AR P160100689 A ARP160100689 A AR P160100689A AR 104020 A1 AR104020 A1 AR 104020A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- compound
- formula
- compositions
- heteroarylalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Composiciones y métodos de uso para inhibir la interacción de menina con las oncoproteínas de fusión MLL1, MLL2 y MLL. Las composiciones y los métodos de uso son de utilidad para el tratamiento de leucemia, cánceres sólidos, diabetes y otras enfermedades dependientes de la actividad de las proteínas de fusión MLL1, MLL2, MLL y/o menina. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo; en donde: H-I es un compuesto de la fórmula (2); cada uno de X¹ y X² es de manera independiente CR² o N; cada uno de X³ y X⁴ es de manera independiente C o N; cada uno de Y¹ y Y² es de manera independiente CR³, N, NR⁴, O ó S; siempre que, cuando X¹ es CR², X² es CR² o N, X³ es C, X⁴ es C y uno de Y¹ y Y² es S, entonces el otro de Y¹ o Y² es N; cada uno de L¹ y L² es de manera independiente un enlace, carbonilo, O, S, -NR⁵-, -NR⁶CH₂-, -NR⁶C(=O)-, -NR⁶SO₂-, alquileno, alquenileno, heteroalquileno, alquilencarbonilo, alquenilencarbonilo, o heteroalquilencarbonilo; A es un enlace, un anillo saturado de 3 - 7 miembros, o un anillo insaturado de 3 - 7 miembros; n es un número entero entre 0 y 12; B se selecciona entre B-I, B-II, B-III y B-IV; en donde B está conectado a través de cualquier átomo del anillo a L²; B-I es un compuesto de la fórmula (3); B-II es un compuesto de la fórmula (4); B-III es un compuesto de la fórmula (5); B-IV es un compuesto de la fórmula (6); cada uno de Z¹, Z², Z³ y Z⁴ es de manera independiente CR⁷, N, o NR⁹; Z⁵ es C o N; cada uno de Z⁶, Z⁷ y Z⁸ es de manera independiente CR⁸, N, NR⁹, O ó S; cada uno de Z⁹, Z¹⁰ y Z¹¹ es de manera independiente CR¹⁰, CR¹¹R¹², NR¹³, O ó S; n es un número entero entre 0 y 6; cada uno de R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² y R¹³ se selecciona, en cada caso, de manera independiente entre H, halo, hidroxilo, amino, ciano, óxido de dialquilfosfina, oxo, carboxilo, amido, acilo, alquilo, cicloalquilo, heteroalquilo, haloalquilo, aminoalquilo, hidroxialquilo, alcoxi, alquilamino, cicloalquilalquilo, cicloalquiloxi, cicloalquilalquiloxi, cicloalquilamino, cicloalquilalquilamino, heterociclilo, heterociclilalquilo, heterocicliloxi, heterociclilalquiloxi, heterociclilamino, heterociclilalquilamino, arilo, aralquilo, ariloxi, aralquiloxi, arilamino, aralquilamino, heteroarilo, heteroarilalquilo, heteroariloxi, heteroarilalquiloxi, heteroarilamino y heteroarilalquilamino; y cada uno de RA y RB se selecciona, en cada caso, de manera independiente entre halo, hidroxilo, amino, ciano, óxido de dialquilfosfina, oxo, carboxilo, amido, acilo, alquilo, cicloalquilo, heteroalquilo, haloalquilo, aminoalquilo, hidroxialquilo, alcoxi, alquilamino, cicloalquilalquilo, cicloalquiloxi, cicloalquilalquiloxi, cicloalquilamino, cicloalquilalquilamino, heterociclilo, heterociclilalquilo, heterocicliloxi, heterociclilalquiloxi, heterociclilamino, heterociclilalquilamino, arilo, aralquilo, ariloxi, aralquiloxi, arilamino, aralquilamino, heteroarilo, heteroarilalquilo, heteroariloxi, heteroarilalquiloxi, heteroarilamino y heteroarilalquilamino, en donde dos grupos RA o dos grupos RB unidos al mismo átomo o a átomos diferentes opcionalmente pueden formar juntos un puente o un anillo.
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310178059.9A CN116217581A (zh) | 2015-06-04 | 2016-03-16 | 用于抑制多发性内分泌抑癌蛋白与mll蛋白质的相互作用的方法及组合物 |
DK16803881.8T DK3303317T3 (da) | 2015-06-04 | 2016-03-16 | Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner |
EP21193636.4A EP4006030A3 (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
EA201792583A EA035141B1 (ru) | 2015-06-04 | 2016-03-16 | Способы и композиции для ингибирования взаимодействия менина с белками mll |
EP16803881.8A EP3303317B1 (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
JP2017558557A JP6730321B2 (ja) | 2015-06-04 | 2016-03-16 | メニンとmllタンパク質との相互作用を阻害する方法及び組成物 |
PCT/US2016/022717 WO2016195776A1 (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
AU2016270002A AU2016270002B2 (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
KR1020187000217A KR102626673B1 (ko) | 2015-06-04 | 2016-03-16 | 메닌과 mll 단백질의 상호작용의 억제를 위한 방법 및 조성물 |
CN201680046005.5A CN107922378A (zh) | 2015-06-04 | 2016-03-16 | 用于抑制多发性内分泌抑癌蛋白与mll蛋白质的相互作用的方法及组合物 |
PT168038818T PT3303317T (pt) | 2015-06-04 | 2016-03-16 | Métodos e composições para inibição da interação de menina com proteínas llm |
PL16803881T PL3303317T3 (pl) | 2015-06-04 | 2016-03-16 | Sposoby i kompozycje do hamowania interakcji meniny z białkami mll |
MA043515A MA43515A (fr) | 2015-06-04 | 2016-03-16 | Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll |
ES16803881T ES2902501T3 (es) | 2015-06-04 | 2016-03-16 | Métodos y composiciones para inhibir la interacción de menina con proteínas MLL |
MX2017015467A MX2017015467A (es) | 2015-06-04 | 2016-03-16 | Metodos y composiciones para inhibir la interaccion de menina con proteinas de mll. |
BR112017026085-9A BR112017026085B1 (pt) | 2015-06-04 | 2016-03-16 | Métodos e composições para a inibição da interação da menin com proteínas da mll |
CA2985053A CA2985053C (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
IL255701A IL255701B (en) | 2015-06-04 | 2017-11-15 | Methods and preparations for inhibiting the interaction of menin with mll proteins |
ZA2017/07848A ZA201707848B (en) | 2015-06-04 | 2017-11-20 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
PH12017502188A PH12017502188A1 (en) | 2015-06-04 | 2017-11-29 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
US15/829,604 US10077271B2 (en) | 2015-06-04 | 2017-12-01 | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
HK18105970.3A HK1246298A1 (zh) | 2015-06-04 | 2018-05-08 | 用於抑制menin蛋白與mll蛋白的相互作用的方法及組合物 |
US16/014,996 US10174041B2 (en) | 2015-06-04 | 2018-06-21 | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562171108P | 2015-06-04 | 2015-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104020A1 true AR104020A1 (es) | 2017-06-21 |
Family
ID=58608916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100689A AR104020A1 (es) | 2015-06-04 | 2016-03-15 | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
Country Status (22)
Country | Link |
---|---|
US (2) | US10077271B2 (es) |
EP (2) | EP4006030A3 (es) |
JP (1) | JP6730321B2 (es) |
KR (1) | KR102626673B1 (es) |
CN (2) | CN107922378A (es) |
AR (1) | AR104020A1 (es) |
AU (1) | AU2016270002B2 (es) |
CA (1) | CA2985053C (es) |
DK (1) | DK3303317T3 (es) |
EA (1) | EA035141B1 (es) |
ES (1) | ES2902501T3 (es) |
HK (1) | HK1246298A1 (es) |
IL (1) | IL255701B (es) |
MA (1) | MA43515A (es) |
MX (1) | MX2017015467A (es) |
MY (1) | MY186712A (es) |
PH (1) | PH12017502188A1 (es) |
PL (1) | PL3303317T3 (es) |
PT (1) | PT3303317T (es) |
TW (1) | TWI703150B (es) |
WO (1) | WO2016195776A1 (es) |
ZA (1) | ZA201707848B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
BR112018068702A2 (pt) | 2016-03-16 | 2019-01-15 | Kura Oncology Inc | inibidores bicíclicos em ponte de menin-mll e métodos de uso |
RS64261B1 (sr) | 2016-03-16 | 2023-07-31 | Kura Oncology Inc | Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe |
AU2017259436B2 (en) | 2016-05-02 | 2021-08-26 | The Regents Of The University Of Michigan | Piperidines as menin inhibitors |
WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
JP6751203B2 (ja) | 2016-06-07 | 2020-09-02 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドJacobio Pharmaceuticals Co., Ltd. | Shp2阻害剤として有用な新規複素環式誘導体 |
JP7033141B2 (ja) | 2016-09-14 | 2022-03-09 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン-mll相互作用の縮合二環式阻害剤 |
AU2017326487B2 (en) | 2016-09-14 | 2021-08-05 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
KR102513564B1 (ko) * | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
NZ758458A (en) | 2017-03-23 | 2022-07-29 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
FI3604304T3 (fi) * | 2017-03-23 | 2022-12-15 | Pyrrolopyridiinijohdannaisyhdiste, menetelmä sen valmistamiseksi ja sitä vaikuttavana ainesosana sisältävä farmaseuttinen koostumus proteiinikinaasiin liittyvien tautien ehkäisemiseksi tai hoitamiseksi | |
US11944627B2 (en) * | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
EA201992320A1 (ru) | 2017-03-31 | 2020-04-22 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Пиперидины в качестве ковалентных ингибиторов менина |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US20200246347A1 (en) | 2017-06-13 | 2020-08-06 | Bayer Pharma Aktiengesellschaft | Substituted Pyrrolopyridine-Derivatives |
CA3066859A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
CA3079060A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
WO2019016071A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES |
TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
AU2018389145B2 (en) * | 2017-12-20 | 2023-02-02 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
CN112105621B (zh) | 2018-03-30 | 2024-02-20 | 住友制药株式会社 | 光学活性桥型环状仲胺衍生物 |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
MX2021000100A (es) | 2018-07-13 | 2021-03-25 | Gilead Sciences Inc | Inhibidores de muerte programada-1 (pd-1)/ ligando de muerte programada 1 (pd-l1). |
CN113164443A (zh) * | 2018-09-26 | 2021-07-23 | 库拉肿瘤学公司 | 用多发性内分泌抑癌蛋白抑制剂治疗血液***恶性肿瘤 |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US20230030720A1 (en) * | 2018-12-06 | 2023-02-02 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
US20220047603A1 (en) | 2018-12-11 | 2022-02-17 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
CA3154136A1 (en) * | 2019-09-20 | 2021-03-25 | Novartis Ag | Mll1 inhibitors and anti-cancer agents |
MX2022015410A (es) | 2020-06-05 | 2023-03-13 | Kinnate Biopharma Inc | Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos. |
WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
CN114516873A (zh) * | 2020-11-18 | 2022-05-20 | 苏州优理生物医药科技有限公司 | 一种螺环类化合物、包含其药物组合物及其应用 |
EP4262986A1 (en) * | 2020-12-16 | 2023-10-25 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
WO2022167627A1 (en) | 2021-02-05 | 2022-08-11 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
KR20240005747A (ko) | 2021-05-08 | 2024-01-12 | 얀센 파마슈티카 엔브이 | 치환된 스피로 유도체 |
EP4334310A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories |
CA3218340A1 (en) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
CN117597348A (zh) | 2021-06-17 | 2024-02-23 | 詹森药业有限公司 | 用于治疗诸如癌症的疾病的(r)-n-乙基-5-氟-n-异丙基-2-((5-(2-(6-((2-甲氧基乙基)(甲基)氨基)-2-甲基己-3-基)-2,6-二氮杂螺[3.4]辛-6-基)-1,2,4-三嗪-6-基)氧基)苯甲酰胺苯磺酸盐 |
CN115515958B (zh) * | 2021-08-04 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
US20240041865A1 (en) * | 2022-07-14 | 2024-02-08 | Huyabio International, Llc | Combination therapies of wdr-5 inhibitors and pd-1 inhibitors |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
US5863A (en) | 1848-10-17 | Matthias p | ||
US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
US510A (en) | 1837-12-07 | soeel | ||
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
TR199900066T2 (xx) | 1996-07-18 | 1999-04-21 | Pfizer Inc. | Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri |
IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
PL335027A1 (en) | 1997-02-03 | 2000-03-27 | Pfizer Prod Inc | Derivatives of arylsulphonylamino hydroxamic acid |
CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
US6479487B1 (en) * | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
ATE402164T1 (de) | 2001-04-26 | 2008-08-15 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
MXPA03009925A (es) | 2001-04-30 | 2004-06-30 | Bayer Pharmaceuticals Corp | Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas. |
AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
WO2004030672A1 (en) | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
WO2004030671A2 (en) | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
NZ542236A (en) | 2003-03-31 | 2008-05-30 | Predix Pharmaceuticals Holding | New piperidinylamino-thieno[2,3-d]pyrimidine compounds |
US8362264B2 (en) | 2003-08-22 | 2013-01-29 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with Trp-p8 expression |
US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
CN101031551A (zh) | 2004-07-06 | 2007-09-05 | 安吉永生物制药公司 | 针对癌症治疗的肝细胞生长因子/c-met活性的喹唑啉调节剂 |
CA2610655A1 (en) | 2005-06-03 | 2006-12-14 | Abbott Laboratories | Cyclobutyl amine derivatives |
US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
JP2009507004A (ja) | 2005-09-02 | 2009-02-19 | テイボテク・フアーマシユーチカルズ・リミテツド | Hcv阻害剤としてのベンゾジアゼピン |
EA200802118A1 (ru) | 2006-04-07 | 2009-04-28 | Девелоджен Ациенгезельшафт | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях |
US8242078B2 (en) | 2006-10-19 | 2012-08-14 | The University Of Chicago | Therapeutics to inhibit MLL-menin interaction for treating leukemia |
EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
WO2008099019A1 (en) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
US8309726B2 (en) | 2007-03-19 | 2012-11-13 | Council Of Scientific & Industrial Research | Substituted piperazine compounds of formula 8 |
WO2008135232A1 (en) * | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
EP2148944A1 (en) | 2007-05-25 | 2010-02-03 | Burnham Institute for Medical Research | Inhibitors of thapsigargin-induced cell death |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
US20110124649A1 (en) | 2007-11-09 | 2011-05-26 | The Johns Hopkins University | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US20100063047A1 (en) | 2008-09-10 | 2010-03-11 | Kalypsys, Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
WO2011003418A1 (en) | 2009-07-08 | 2011-01-13 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
EP2473054B1 (en) | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
GB201217704D0 (en) * | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
JP2016512514A (ja) | 2013-03-13 | 2016-04-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法 |
US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
HUE042753T2 (hu) | 2014-04-04 | 2019-07-29 | Syros Pharmaceuticals Inc | A ciklin-dependens kináz 7 enzim (CDK 7) inhibitorai |
US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
USRE49687E1 (en) * | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
BR112018012707A2 (pt) | 2015-12-22 | 2019-01-29 | Vitae Pharmaceuticals Inc | inibidores da interação de menin-mll |
AU2017212572A1 (en) | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
RS64261B1 (sr) | 2016-03-16 | 2023-07-31 | Kura Oncology Inc | Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe |
BR112018068702A2 (pt) | 2016-03-16 | 2019-01-15 | Kura Oncology Inc | inibidores bicíclicos em ponte de menin-mll e métodos de uso |
AU2017259436B2 (en) | 2016-05-02 | 2021-08-26 | The Regents Of The University Of Michigan | Piperidines as menin inhibitors |
WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
LT3468966T (lt) | 2016-06-10 | 2021-02-25 | Vitae Pharmaceuticals, Llc | Menino-mll sąveikos inhibitoriai |
WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
JP7033141B2 (ja) | 2016-09-14 | 2022-03-09 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン-mll相互作用の縮合二環式阻害剤 |
TWI738864B (zh) | 2016-09-14 | 2021-09-11 | 比利時商健生藥品公司 | Menin-mll相互作用之螺二環抑制劑 |
RU2019111169A (ru) | 2016-09-16 | 2020-10-20 | ВИТЭ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Ингибиторы взаимодействия менин-mll |
-
2016
- 2016-03-15 AR ARP160100689A patent/AR104020A1/es unknown
- 2016-03-15 TW TW105108013A patent/TWI703150B/zh active
- 2016-03-16 EP EP21193636.4A patent/EP4006030A3/en active Pending
- 2016-03-16 DK DK16803881.8T patent/DK3303317T3/da active
- 2016-03-16 JP JP2017558557A patent/JP6730321B2/ja active Active
- 2016-03-16 CA CA2985053A patent/CA2985053C/en active Active
- 2016-03-16 PT PT168038818T patent/PT3303317T/pt unknown
- 2016-03-16 MA MA043515A patent/MA43515A/fr unknown
- 2016-03-16 MY MYPI2017001731A patent/MY186712A/en unknown
- 2016-03-16 KR KR1020187000217A patent/KR102626673B1/ko active IP Right Grant
- 2016-03-16 WO PCT/US2016/022717 patent/WO2016195776A1/en active Application Filing
- 2016-03-16 EP EP16803881.8A patent/EP3303317B1/en active Active
- 2016-03-16 MX MX2017015467A patent/MX2017015467A/es unknown
- 2016-03-16 CN CN201680046005.5A patent/CN107922378A/zh active Pending
- 2016-03-16 ES ES16803881T patent/ES2902501T3/es active Active
- 2016-03-16 PL PL16803881T patent/PL3303317T3/pl unknown
- 2016-03-16 AU AU2016270002A patent/AU2016270002B2/en active Active
- 2016-03-16 EA EA201792583A patent/EA035141B1/ru unknown
- 2016-03-16 CN CN202310178059.9A patent/CN116217581A/zh active Pending
-
2017
- 2017-11-15 IL IL255701A patent/IL255701B/en active IP Right Grant
- 2017-11-20 ZA ZA2017/07848A patent/ZA201707848B/en unknown
- 2017-11-29 PH PH12017502188A patent/PH12017502188A1/en unknown
- 2017-12-01 US US15/829,604 patent/US10077271B2/en active Active
-
2018
- 2018-05-08 HK HK18105970.3A patent/HK1246298A1/zh unknown
- 2018-06-21 US US16/014,996 patent/US10174041B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR104020A1 (es) | Métodos y composiciones para inhibir la interacción de menina con proteínas mill | |
AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
AR099824A1 (es) | Compuestos bicíclicos | |
AR115978A1 (es) | Compuesto con anillos fusionados | |
AR117616A1 (es) | Compuestos anti-vih | |
AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR087348A1 (es) | Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos | |
AR095464A1 (es) | Compuestos de heteroarilo y usos de los mismos | |
AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
AR112804A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos | |
AR103561A1 (es) | Fenilpiridinas herbicidas | |
AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
AR094816A2 (es) | Compuestos antivirales | |
AR113965A1 (es) | Triazol azoles ciclohexil ácidos como antagonistas de lpa | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
AR104512A1 (es) | Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
AR117978A1 (es) | Inhibidores de 15-pgdh | |
AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
AR109487A1 (es) | Derivados de imidazo-2-il-piridin-2-ona como inhibidores de la unión de las proteínas bet | |
AR100448A1 (es) | 5-(hetero)aril-piridazinonas y su uso como herbicida | |
AR118119A1 (es) | Compuestos de pirido-pirimidinilo y métodos de uso | |
AR085352A1 (es) | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |